FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207745> ?p ?o ?g. }

• W4387207745 endingPage "e365" @default.
• W4387207745 startingPage "e365" @default.
• W4387207745 abstract "Retrospective studies have suggested that post-operative radiation therapy (RT) can reduce the risk of cause-specific mortality in men with pathologic nodal involvement (pN1) after radical prostatectomy (RP). We evaluated prognostic factors and patterns of recurrence in patients who received post-operative RT +/- androgen deprivation therapy (ADT) for pN1 disease in a multicentric cohort of 4 academic centers.Data from patients with pN1 prostate cancer after RP who subsequently received RT with short term (< = 6 mo) or long term (>6 mo) ADT were obtained from 4 academic institutions. Patterns of recurrence, biochemical progression free survival (bPFS) and distant metastasis free survival (DMFS) were evaluated.A total of 270 patients with a median follow-up of 48 months were included. Gleason grade group (GG) 2 was present in 20 patients (7.5%), GG 3 in 81 (30%), GG4 in 36 (13.5%), GG5 in 130 (49%) patients. 256 (95%) patients had extracapsular extension, 70% had seminal vesicle invasion, 59% had positive surgical margins, and 66% had a detectable post-operative PSA. The number of positive nodes at surgery were 1 in 59%, 2 in 19% and >2 in 22% of patients. Of the 83 patients that had pre-RT imaging, 46 (55%) had a PET scan (PSMA, or fluciclovine); 25 (30%) of those had lymph nodes detected on imaging prior to RT. Median time from RP to RT was 6 mo (IQR 4.5-9.1 mo). 96% received radiation to both the prostate bed (median dose 68.4Gy) and pelvic lymph nodes (median dose 46Gy). ADT was prescribed short-term (20%) or long-term (68%), while 26 (10%) received no ADT, and 7 (3%) had an unknown duration. Biochemical failure (bF) was observed in 29% of men, with 5% having pelvic nodal failure and 11.5% having distant metastases (majority in bones, followed by paraaortic nodes) at last follow up. Of 59 patients who had normal baseline testosterone levels, 37% recovered their testosterone by last follow-up. The 4-year bRFS was 72% for all patients and was 83% for those with a pre-RT PSA of <0.1 ng/mL, 76% for PSA 0.1-<0.5 ng/mL, 60% for PSA 0.5-2 ng/mL, and 35% for PSA >2 ng/mL. On multivariable analysis, maximum pre-RT PSA ≥0.5 (0.5 to 2.0 vs <0.1 HR = 3.19; >2.0 vs <0.1 HR = 9.00), use of LTADT (HR = 0.47), and percent pN1 (HR = 1.03) were significantly associated with bF. Pre-RT PSA >2 (HR = 4.10), use of LT ADT (HR = 0.33) and percent pN1 (HR = 1.03) were also significantly associated with DM.In pN1 patients, pelvic RT and ADT at low PSA levels is associated with improved oncologic outcomes compared to treatment at higher levels, suggesting that PSA may have prognostic value for pN1 prostate cancer." @default.
• W4387207745 created "2023-09-30" @default.
• W4387207745 creator A5004894140 @default.
• W4387207745 creator A5019423508 @default.
• W4387207745 creator A5025246130 @default.
• W4387207745 creator A5037174103 @default.
• W4387207745 creator A5057040034 @default.
• W4387207745 creator A5058687400 @default.
• W4387207745 creator A5065133140 @default.
• W4387207745 creator A5066928967 @default.
• W4387207745 creator A5073453958 @default.
• W4387207745 creator A5077358252 @default.
• W4387207745 creator A5078447958 @default.
• W4387207745 creator A5078970921 @default.
• W4387207745 date "2023-10-01" @default.
• W4387207745 modified "2023-10-06" @default.
• W4387207745 title "Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node Positive Prostate Cancer: A Multi-Institutional Study" @default.
• W4387207745 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2459" @default.
• W4387207745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785252" @default.
• W4387207745 hasPublicationYear "2023" @default.
• W4387207745 type Work @default.
• W4387207745 citedByCount "0" @default.
• W4387207745 crossrefType "journal-article" @default.
• W4387207745 hasAuthorship W4387207745A5004894140 @default.
• W4387207745 hasAuthorship W4387207745A5019423508 @default.
• W4387207745 hasAuthorship W4387207745A5025246130 @default.
• W4387207745 hasAuthorship W4387207745A5037174103 @default.
• W4387207745 hasAuthorship W4387207745A5057040034 @default.
• W4387207745 hasAuthorship W4387207745A5058687400 @default.
• W4387207745 hasAuthorship W4387207745A5065133140 @default.
• W4387207745 hasAuthorship W4387207745A5066928967 @default.
• W4387207745 hasAuthorship W4387207745A5073453958 @default.
• W4387207745 hasAuthorship W4387207745A5077358252 @default.
• W4387207745 hasAuthorship W4387207745A5078447958 @default.
• W4387207745 hasAuthorship W4387207745A5078970921 @default.
• W4387207745 hasConcept C121608353 @default.
• W4387207745 hasConcept C126322002 @default.
• W4387207745 hasConcept C126894567 @default.
• W4387207745 hasConcept C142724271 @default.
• W4387207745 hasConcept C143998085 @default.
• W4387207745 hasConcept C167135981 @default.
• W4387207745 hasConcept C2776235491 @default.
• W4387207745 hasConcept C2777008409 @default.
• W4387207745 hasConcept C2777899217 @default.
• W4387207745 hasConcept C2779013556 @default.
• W4387207745 hasConcept C2779466945 @default.
• W4387207745 hasConcept C2779720271 @default.
• W4387207745 hasConcept C2780192828 @default.
• W4387207745 hasConcept C2780849966 @default.
• W4387207745 hasConcept C509974204 @default.
• W4387207745 hasConcept C71924100 @default.
• W4387207745 hasConcept C72563966 @default.
• W4387207745 hasConceptScore W4387207745C121608353 @default.
• W4387207745 hasConceptScore W4387207745C126322002 @default.
• W4387207745 hasConceptScore W4387207745C126894567 @default.
• W4387207745 hasConceptScore W4387207745C142724271 @default.
• W4387207745 hasConceptScore W4387207745C143998085 @default.
• W4387207745 hasConceptScore W4387207745C167135981 @default.
• W4387207745 hasConceptScore W4387207745C2776235491 @default.
• W4387207745 hasConceptScore W4387207745C2777008409 @default.
• W4387207745 hasConceptScore W4387207745C2777899217 @default.
• W4387207745 hasConceptScore W4387207745C2779013556 @default.
• W4387207745 hasConceptScore W4387207745C2779466945 @default.
• W4387207745 hasConceptScore W4387207745C2779720271 @default.
• W4387207745 hasConceptScore W4387207745C2780192828 @default.
• W4387207745 hasConceptScore W4387207745C2780849966 @default.
• W4387207745 hasConceptScore W4387207745C509974204 @default.
• W4387207745 hasConceptScore W4387207745C71924100 @default.
• W4387207745 hasConceptScore W4387207745C72563966 @default.
• W4387207745 hasIssue "2" @default.
• W4387207745 hasLocation W43872077451 @default.
• W4387207745 hasLocation W43872077452 @default.
• W4387207745 hasOpenAccess W4387207745 @default.
• W4387207745 hasPrimaryLocation W43872077451 @default.
• W4387207745 hasRelatedWork W1995533274 @default.
• W4387207745 hasRelatedWork W1998796379 @default.
• W4387207745 hasRelatedWork W2117050434 @default.
• W4387207745 hasRelatedWork W2402249956 @default.
• W4387207745 hasRelatedWork W2545489389 @default.
• W4387207745 hasRelatedWork W2795593732 @default.
• W4387207745 hasRelatedWork W2904168711 @default.
• W4387207745 hasRelatedWork W3150909901 @default.
• W4387207745 hasRelatedWork W4319748405 @default.
• W4387207745 hasRelatedWork W193188344 @default.
• W4387207745 hasVolume "117" @default.
• W4387207745 isParatext "false" @default.
• W4387207745 isRetracted "false" @default.
• W4387207745 workType "article" @default.